Retinoid Differentiation Therapy for Common Types of Acute Myeloid Leukemia

<table>Influence of inhibiting the activity of AKR1C3 on PGD<sub>2</sub> metabolism. Inhibiting the activity of AKR1C3 by the use of indomethacin or medroxyprogesterone acetate (MPA) interferes with prostaglandin D<sub>2</sub> (PGD<sub>2</sub>) metabolism towards 9<i>α</i>,11<i>β</i> PGF<sub>2</sub> and favours nonenzymatic metabolism towards J-series prostanoids and the PPAR<i>γ</i> ligand 15-deoxy-Δ12,14-PGJ<sub>2</sub>.</table>

Leukemia Research and Treatment

fig1

Figure 1

Figure 1: Retinoid Differentiation Therapy for Common Types of Acute Myeloid Leukemia 